VT
ALNY icon

Vise Technologies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vise Technologies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Sell
1,242
-273
-18% -$82.3K ﹤0.01% 1327
2026
Q1 		$602K Hold
1,515
– – 0.01% 785
2025
Q4 		$602K Buy
1,515
+491
+48% +$217K 0.01% 790
2025
Q3 		$467K Sell
1,024
-310
-23% -$126K 0.02% 694
2025
Q2 		$435K Buy
+1,334
New +$369K 0.02% 697

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vise Technologies's ALNY Position: Q2 2026 in Review

Vise Technologies reduced its Alnylam Pharmaceuticals (ALNY) stake by 18% in Q2 2026, selling an estimated $82.3K and leaving 1,242 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

Vise Technologies first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $602K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vise Technologies held 1,242 shares of Alnylam Pharmaceuticals worth $374K as of Q2 2026.
  • Vise Technologies sold 273 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $82.3K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Vise Technologies's portfolio in Q2 2026, its #1327 holding.
  • Vise Technologies first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Vise Technologies's Alnylam Pharmaceuticals position peaked at $602K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.